Introduction
cancer, endometrial cancer, TCGA, Endometrial cancer
CANCER, ENDOMETRIAL CANCER, ENDOMETRIAL CANCER
Endometrial cancer is the sixth most common cause of cancer in females with 417,000 cases every year [Lurbinectedin (ZEPZELCAThis report focuses on the outcomes of the endometrial cancer cohort. In addition, retrospective biomarker analysis based on TCGA and PromiSe molecular subtypes was explored. This cohort was evaluated because promising antitumor activity was previously found in a phase I study for a combination of doxorubicin plus lurbinectedin in patients with advanced endometrial cancer [